NewAmsterdam COO Douglas Kling resigns to become CEO of another biotech; transition expected

NewAmsterdam Pharma Co N.V.

Douglas Kling notified resignation as COO effective August 14, 2026.
Kling will become CEO of another clinical-stage biotech company.
Company expects separation agreement and advisor agreement for transition services.
Advisor role will focus on PREVAIL clinical trial of obicetrapib and other programs.
No replacement for COO announced.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.